Altered oxygen affinity variant hemoglobins (Hbs) are caused by mutations of the globin genes.
| INTRODUCTION AND CASES

| Case 1: low oxygen affinity variant Hb
A 37-year-old man was referred with a history of longstanding low oxygen saturation measurements by pulse oximetry (SpO 2 ) in the range of 86% to 89% and suspicion of an altered oxygen affinity variant hemoglobin (Hb). His family history was negative for any hematologic disorders or known variant Hbs; however, his child also had low SpO 2 readings. The patient was clinically asymptomatic.
Initial cardio-respiratory work-up was completed by an internist, including the following tests, with no abnormalities identified: chest x-ray, pulmonary function testing, echocardiogram, two Holter monitor recordings and an exercise stress test. An arterial blood gas (ABG) was done and the results were: P a O 2 90 mm Hg (normal 80-100 mm Hg), In our clinic, physical examination revealed blood pressure 116/77, heart rate 58 and SpO 2 91% on room air. There was no cyanosis, pallor, jaundice or plethora. His hands appeared normal and nails were intact without any polish or scarring that could interfere with pulse oximetry readings. There was no lymphadenopathy. Cardiac, respiratory and abdominal exams were normal.
His compete blood count (CBC) revealed Hb 13.7 g/dL, white blood cell count (WBC) 5.6 × 10 9 /L and platelets 177 × 10 9 /L. An ABG was repeated, with results similar to previous. High-performance liquid chromatography (HPLC) analysis of Hb indicated the following fractions: Hb A 76.6%, Hb X (variant) 20.6%, Hb A2 2.2% and Hb X2
(variant) 0.6%. These results were suggestive of an alpha globin chain variant. The partial pressure of 50% saturation of Hb (p50) was measured on hemolysate and was elevated at 27.5 m Hg (normal 24-27 mm Hg), consistent with a low oxygen affinity variant.
DNA analysis identified heterozygosity for the Hb Kirksey mutation of the alpha-2 gene (HBA2), a known low oxygen affinity Hb variant caused by a point mutation at codon 94 (GAC to GTC), resulting in a substitution of aspartic acid to valine. 1 We completed Hb absorption spectrum testing which showed a normal pattern of light absorption compared with control sample in the range of 600 to 1100 nm. Additional investigations included a negative hemolytic screen and normal bleeding. The patient was started on therapeutic dose low molecular weight heparin. She had been using the Evra patch (norelgestromin and ethinyl estradiol) for almost 1 year, and this was discontinued.
Her previous history of exposure to hormone therapy included attempted intrauterine insemination and in vitro fertilization (IVF) 3 years prior, which did not result in pregnancy or in any treatmentassociated complications. During IVF planning, thrombophilia screening had been completed and was negative for activated protein C resistance, anticardiolipin antibodies and nonspecific inhibitor. Antithrombin levels, free protein S levels and protein C function were all within normal limits. The V617F JAK2 mutation was negative.
Several family members from the paternal side had also been diagnosed with heterozygosity for Hb Potomac, and several had been treated with therapeutic phlebotomy (see family pedigree in Figure 1 ).
No affected family members had a known history of thrombosis. The paternal grandmother died from a cerebral hemorrhage at the age of 30-although it was suspected that she had Hb Potomac, her status could not be confirmed as there was no documented blood testing on file.
On outpatient follow-up 3 weeks after discharge, our patient reported significant improvement in her headache. A total of three therapeutic phlebotomies had been performed since initial presentation. She had stopped all hormonal therapy and was receiving thera- With regard to oxygen delivery, high affinity variants become fully saturated with oxygen in the lung, but at a tissue capillary pO 2 of 35 to 45 mm Hg, they deliver less oxygen than normal Hb A. This results in mild tissue hypoxia which stimulates increased erythropoietin production and subsequent polycythemia. Low oxygen affinity variants are in many ways opposite to high affinity variants; at a normal lung pO 2 of 90 to 100 mm Hg, most low affinity variants become fully saturated. 8 However, since low affinity Hbs have stabilization of the T-state and destabilization of the R-state, these variants are more Israel, Hb Richmond and Hb Saint Mandé). 7, 9 The residue at position 102 of the β-globin chain is an invariant asparagine that participates in the only hydrogen bond across the α1β2 interface in oxyhemoglobin, with mutation of this residue causing stabilization of the T state and reduced oxygen affinity.
3 | CLINICAL FEATURES
| Low oxygen affinity variant hemoglobins
Low oxygen affinity variants can present with cyanosis, hypoxemia, reduced pulse oximetry measurements and/or normocytic anemia.
Asymptomatic anemia is a common physiologic consequence of decreased oxygen affinity, with increased oxygen delivery to the tissues leading to compensatory decrease in erythropoiesis. Chronically low SpO 2 has been documented in patients with a number of low oxygen affinity variants, including Hb Rothschild, Bassett and Chico. [10] [11] [12] Incongruence between the patient's clinically stable physical evaluation and low SpO 2 is explained by increased tissue oxygen delivery by the low affinity variant. 10, 13 Studies in animals with low affinity Hb have demonstrated gain of function compared to normal, including decreased left ventricular work, enhanced tissue oxygenation and consumption, and increased exercise capacity. 10, 14, 15 A p50 measurement should be considered in any patient with any longstanding and otherwise unexplained signs and symptoms as above, especially in the presence of a clear family history. 7 
| High oxygen affinity variant hemoglobins
Patients generally present with polycythemia, often accompanied by a ruddy complexion and mucosal erythema. The clinical course may be complicated by thrombotic events and/or symptoms of hyperviscosity, FIGURE 2 Hemoglobin oxygen association curves. Oxygen saturation curves for adult hemoglobin (Hb A), fetal hemoglobin (Hb F) and myoglobin (Mb). The sigmoidal shapes of oxygen binding to HbA and HbF reflect the cooperativity seen in oxygen binding to subunits. While myoglobin is a monomeric protein that has rapid oxygen-concentration dependent saturation. Notably myoglobin is easily saturated in the peripheral tissues at low partial pressures of oxygen, while hemoglobin requires a higher oxygen tension to become saturated, which occurs in the lungs. The HbF saturation curve is left-shifted in comparison to the curve for HbA, indicating that fetal hemoglobin binds oxygen with higher affinity than does adult hemoglobin, facilitating fetal acquisition of oxygen from the maternal circulation. Figure reproduced with permission of the medical biochemistry page, LLC such as headaches, vertigo, tinnitus, and paresthesia in the extremities. 16 In some, the Hb concentration at diagnosis can be greater than 20 g/dL.
The terms polycythemia and erythrocytosis are often used interchangeably; however, erythrocytosis is defined as a red cell mass that is greater than 125% above that expected for sex and body mass, 17 whereas polycythemia is defined as an increase in Hb concentration and/or HCT above the normal reference range, and does not require documentation of increased red cell mass. Although high oxygen affinity Hbs are primary red blood cell abnormalities, they are categorized as secondary causes of polycythemia since upregulation of EPO drives increased RBC and Hb production. Since these variants have higher avidity for oxygen (ie, lower p50) there is decreased oxygen delivery to the tissues and a resultant increase in EPO. In clinical testing, EPO levels of patients with high affinity variants will be in the normal range when the patient is at his or her baseline HCT, and EPO levels will rise following therapeutic phlebotomy. 16 Most reported patients with high oxygen affinity Hb variants are heterozygous for mutations in a single globin gene; however, homozygous patients have been described who present with more severe disease. 7, 16 Compound heterozygotes for a high affinity variant and a thalassemic gene can present with severe erythrocytosis. 16 Interestingly, roughly two thirds of the high affinity Hbs are not associated with a secondary erythrocytosis. Reasons for this may include lowlevel expression of the variant (eg, an alpha chain mutation) or a concomitant chronic hemolysis if the variant Hb is also unstable.
| DIAGNOSTIC TESTS
The two sets of investigations that should be performed to positively identify an altered oxygen affinity Hb variant are: the p50 test, and studies to detect a variant Hb, such as Hb electrophoresis, HPLC or capillary electrophoresis.
| p50 testing
Oxygen affinity testing is performed using a specialized spectropho- Arterial blood gas is a crucial ancillary test that must be interpreted in conjunction with pulse oximetry readings in patients with with altered absorption spectra. Figure 3B illustrates the example of the unique absorption spectrum of Hb Bonn.
5 | MANAGEMENT
| Low oxygen affinity variant hemoglobins
Low oxygen affinity Hb variants do not require any specific management. However, in those with low SpO 2 , the correct diagnosis is important so as to avoid unnecessary cardiorespiratory investigations and interventions.
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| High oxygen affinity variant hemoglobins
Most individuals with high oxygen affinity Hbs are asymptomatic;
however, thromboembolic events and hyperviscosity symptoms have been reported [29] [30] [31] • Treatment and secondary prevention of thromboembolic complications-Patients with acute thromboembolic complications should be treated with antithrombotic agents as per evidence-based guidelines for the type of thrombotic event. Decisions about intensity and duration of anticoagulation should take into consideration the increased risk of recurrence in the setting of chronic polycythemia.
There have been reports of thrombosis in patients with coexisting high oxygen affinity variant Hb and hereditary thrombophilia, specifically factor V Leiden or protein S deficiency. 32, 33 Following diagnosis of VTE, the patients in these case series' were treated with aspirin or anticoagulants alone rather than phlebotomy. In a separate case report of a 51-year-old male patient with a high affinity Hb-Hb Radcliffe-and no known concurrent thrombophilic defect, the patient was treated with anticoagulants on the first instance of deep vein thrombosis with a concomitant diagnosis of atrial fibrillation. 30 Three years later this patient developed a pulmonary embolism and myocardial infarction, at which point anticoagulants were continued with addition of phlebotomy treatment.
• Treatment of hyperviscosity-Individuals with symptoms of hyperviscosity warrant a trial of therapeutic phlebotomy. Initial phlebotomy of 200 to 500 mL may be performed, with subsequent reassessment of targeting an HCT at which hyperviscosity symptoms are minimized, and ensuring the patient is not experiencing symptoms associated with reduced oxygen-carrying capacity. Guidelines on the investigation and management of erythrocytosis suggest that the target hematocrit with phlebotomy for patients with high affinity Hbs should be <0.60. 30, 34 If thrombosis or symptoms of hyperviscosity occur at lower hematocrits, then a target hematocrit of 0.52 is suggested. 34 In one instance of a woman with Hb Yakima, symptoms of hyperviscosity improved following phlebotomy down to an HCT of 0.52, 35 and there was no difference in the patient's exercise performance pre-phlebotomy and post-phlebotomy, as measured by the maximum time achieved on the Bruce protocol. There are other reports, however, showing decreased exercise performance in patients with high affinity variants following phlebotomy. 36, 37 It is important to note that the target HCT proposed here is higher than that currently employed in patients with polycythemia vera (PV).
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• Asymptomatic patients-There have been no high-quality studies assessing the outcomes associated with phlebotomy for polycy- While the management of low oxygen affinity Hbs is straightforward, the optimal management of high oxygen affinity variants is uncertain and, therefore, must be individualized. For example, at initial presentation with cerebral vein thrombosis, the hematocrit of our patient with Hb Potomac was 0.565, which is lower than the hematocrit target that was proposed in the guidelines by McMullin for asymptomatic patients. 34 Unfortunately, the hematocrit targets for high 
